MTOR and colorectal carcinoma: When comparing dual PI3K/mTOR inhibition with MEK inhibition against PI3K and MEK inhibition, Haagensen et al. found that the pan-PI3K inhibitor GDC-0941 demonstrated greater synergy than the dual PI3K/mTOR inhibitor BEZ235 when combined with the MEK inhibitors selumetinib and PD0325901 in BRAF/PIK3CA-double-mutant HT29 and KRAS/PIK3CA-double-mutant HCT116 CRC cell lines [47].